dc.contributor.author |
Fourie, Josephus J.
|
|
dc.contributor.author |
Liebenberg, Julian E.
|
|
dc.contributor.author |
Horak, Ivan Gerard
|
|
dc.contributor.author |
Taenzler, Janina
|
|
dc.contributor.author |
Heckeroth, Anja R.
|
|
dc.contributor.author |
Frenais, Regis
|
|
dc.date.accessioned |
2015-07-07T09:14:30Z |
|
dc.date.available |
2015-07-07T09:14:30Z |
|
dc.date.issued |
2015-03-28 |
|
dc.description.abstract |
BACKGROUND : This laboratory study compared the efficacy of Bravecto™ (fluralaner), formulated as a chewable
tablet, with the efficacy of Advocate® (imidacloprid/moxidectin), formulated for topical administration, against
naturally acquired generalized demodicosis in dogs.
METHODS : Sixteen dogs, all diagnosed with generalized demodectic mange, were randomly allocated to two equal
groups. Bravecto™ chewable tablets were administered once orally at a minimum dose of 25 mg fluralaner/kg body
weight to one group of dogs, while the second group was treated topically on three occasions at 28-day intervals
with Advocate® at a minimum dose of 10 mg imidacloprid/kg body weight and 2.5 mg moxidectin/kg body weight.
Mites were counted in skin scrapings and demodectic lesions were evaluated on each dog before treatment and at
28-day intervals thereafter over a 12 week study period. Deep skin scrapings (~4 cm2) were made from the same five
sites on each dog at each subsequent examination.
RESULTS : After single oral administration of Bravecto™ chewable tablets, mite numbers in skin scrapings were reduced
by 99.8% on Day 28 and by 100% on Days 56 and 84. Mite numbers in the dogs treated topically on three occasions at
28-day intervals with Advocate® were reduced by 98.0% on Day 28, by 96.5% on Day 56 and by 94.7% on Day 84.
Statistically significantly (P ≤ 0.05) fewer mites were found on Days 56 and 84 on the Bravecto™ treated dogs
compared to Advocate® treated dogs. A marked decrease was observed in the occurrence of erythematous patches,
crusts, casts and scales in the dogs treated with Bravecto™ and in the occurrence of erythematous patches in the dogs
treated with Advocate®. With the exception of one dog in each treated group, all dogs exhibited hair regrowth ≥ 90%
at the end of the study in comparison with their hair-coat at study start.
CONCLUSIONS : Single oral administration of Bravecto™ chewable tablets is highly effective against generalized
demodicosis, with no mites detectable at 56 and 84 days following treatment. In comparison, Advocate®, administered
three times at 28-day intervals, is also highly effective against generalized demodicosis, but most dogs still harboured
mites at all assessment time points. Both treatments resulted in a marked reduction of skin lesions and increase of hair re-growth 12 weeks after the initial treatment. |
en_ZA |
dc.description.librarian |
am2015 |
en_ZA |
dc.description.uri |
http://www.parasitesandvectors.com |
en_ZA |
dc.identifier.citation |
Fourie, JJ, Liebenberg, JE, Horak, IG, Taenzler, J, Heckeroth, AR & Frenais, R 2015, 'Efficacy of orally administered fluralaner (BravectoTM) or topically applied imidacloprid/moxidectin (Advocate®) against generalized demodicosis in dogs', Parasites and Vectors, vol. 8, no. 187, pp. 1-7. |
en_ZA |
dc.identifier.issn |
1756-3305 |
|
dc.identifier.other |
10.1186/s13071-015-0775-8 |
|
dc.identifier.other |
7102989086 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/46310 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
BioMed Central |
en_ZA |
dc.relation.requires |
Adobe Acrobat Reader |
en |
dc.rights |
© 2015 Fourie et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License. |
en_ZA |
dc.subject |
Bravecto™ |
en_ZA |
dc.subject |
Chewable tablets |
en_ZA |
dc.subject |
Fluralaner |
en_ZA |
dc.subject |
Advocate® |
en_ZA |
dc.subject |
Spot-on formulations |
en_ZA |
dc.subject |
Imidacloprid |
en_ZA |
dc.subject |
Moxidectin |
en_ZA |
dc.subject |
Efficacy |
en_ZA |
dc.subject |
Dogs |
en_ZA |
dc.subject |
Generalized demodicosis |
en_ZA |
dc.subject |
Demodex canis |
en_ZA |
dc.subject |
Mange |
en_ZA |
dc.subject |
Scabies |
en_ZA |
dc.subject.lcsh |
Dogs -- Diseases |
en_ZA |
dc.title |
Efficacy of orally administered fluralaner (BravectoTM) or topically applied imidacloprid/moxidectin (Advocate®) against generalized demodicosis in dogs |
en_ZA |
dc.type |
Article |
en_ZA |